Jason Mellad

CEO and Founder
Start Codon

Dr Jason Mellad is a scientist entrepreneur passionate about translating innovative technologies into more effective therapies and better patient outcomes. Prior to founding Start Codon, he was CEO of Cambridge Epigenetix which has developed a proprietary epigenetic biomarker discovery platform for the development of new diagnostic assays and the identification of novel drug targets. Before joining Cambridge Epigenetix, he was a Business Development Manager for Horizon Discovery’s diagnostics division and also served as an Associate at Cambridge Enterprise. He was a Marshall Scholar and obtained his PhD in Medicine from the University of Cambridge with a focus on the molecular mechanisms regulating vascular remodeling within coronary artery bypass grafts. He has a BSc (summa cum laude) in Molecular Biology and Chemistry from Tulane University.